|
Alomone Labs
anti-trpc6 antibody Anti Trpc6 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rabbit+anti+trpc6+antibody/custom%40acc-017%4010%2E1681%2Fasn%2E2018030280?v=Alomone+Labs Average 95 stars, based on 1 article reviews
anti-trpc6 antibody - by Bioz Stars,
2026-07
95/100 stars
|
Buy from Supplier |
|
Merck KGaA
rabbit anti-trpc6 antibody ![]() Rabbit Anti Trpc6 Antibody, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rabbit+anti+trpc6+antibody/pmc10449997-88-23-25?v=Merck+KGaA Average 90 stars, based on 1 article reviews
rabbit anti-trpc6 antibody - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
|
Rabbit anti-Human TRPC6 Polyclonal Antibody
|
Buy from Supplier |
Image Search Results
Journal: Cellular and Molecular Life Sciences
Article Title: An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
doi: 10.1007/s00018-023-04901-w
Figure Lengend Snippet: Design and generation of XLone transgenic HeLa cells. a Schematic design showing the transposable plasmid cassette ( 5′ PB 5′ PiggyBac Terminal Repeat; 3′ PB 3′ PiggyBac Terminal Repeat; MCS multiple cloning sites; Bsd blasticidin resistance gene; EFS EF1 alpha promoter; TRE3G tetracycline responsive element 3G promoter). b Flow cytometry analysis of the cells after Bsd drug selection and FACS-live cell sorting of respective wild type, P112Q, G757D, and V691Kfs*. c Representative images illustrate the expression of YFP reporter (green) after transfection, Bsd selection, and FACs sorting, as shown by the merged image of the bright field and YFP signal for each of the variants studied. Scale bar 50 µm. d Representative FACS plots of transgenic HeLa cells demonstrate an enriched population up to a maximum of 89% YFP-positive cells. e Western blot for TRPC6 protein from wild-type, p112Q, G757D, and V691kfs* (~ 130 kDa) (B) β-actin (~ 45 kDa) in HeLa cells
Article Snippet: The membrane was blocked by Intercept T20 Antibody Diluent (LI-COR Bioscience) for 1 h at room temperature on the shaker and incubated with
Techniques: Transgenic Assay, Plasmid Preparation, Clone Assay, Flow Cytometry, Selection, FACS, Expressing, Transfection, Western Blot
Journal: Cellular and Molecular Life Sciences
Article Title: An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
doi: 10.1007/s00018-023-04901-w
Figure Lengend Snippet: Tridimensional cryo-EM structure of tetrameric TRPC6 (PDB: 6UZ8) indicating novel truncated p.Val691Lysfs*2 (V691Kfs*) ([STOP]AA692) protein in exon 8. a View from the extracellular side, representing four monomeric TRPC6 subunits forming the ion channel complex. b Close-up view of the helices shows an exchange of Valine to Lysine at amino acid position p.691 and in a stop codon at p.692 making a truncated protein. c Full homology view parallel to the membrane. The location of the V691 protein is indicated in dark blue color and red color illustrates the truncated part of the closed channel. d Truncation results in complete loss of the C-terminal helices. e Verification of c.2060_2070dup AAGTGAAATCA variant compared with wild-type TRPC6 sequence. f Comparison of variant sequence with nucleotide insertion and addition of stop codon at p.692, with wild-type TRPC6 sequence
Article Snippet: The membrane was blocked by Intercept T20 Antibody Diluent (LI-COR Bioscience) for 1 h at room temperature on the shaker and incubated with
Techniques: Cryo-EM Sample Prep, Variant Assay, Sequencing
Journal: Cellular and Molecular Life Sciences
Article Title: An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
doi: 10.1007/s00018-023-04901-w
Figure Lengend Snippet: Functional characterization reveals GOF, LOF, and truncated phenotype in FSGS-related TRPC6 mutations. Changes in intracellular Ca 2+ concentration ( F / F 0 ) were measured in Fluo-4 AM-loaded HeLa cells pretreated with doxycycline (Dox) (24 h prior) expressing either wild type (WT), P112Q, G757D, or V691Kfs*. Each condition was carried out in replicates, while un-transfected HeLa cells served as control. a Carbachol (Cch) (100 µM) was added 20 s after the start of the measurement. Representative measurement for all samples is shown in the upper panel, while a summary is presented as a bar graph ( n = 3, mean ± SEM) in the lower panel. The graph shows the differences in amplitudes of the responses to Cch. b DOG (100 µM) was added 20 s after the start of the measurement. Representative measurement for all samples is shown in the upper panel, while a summary is presented as a bar graph ( n = 3, mean ± SEM) in the lower panel. The graph shows the differences in amplitudes of the responses to DOG
Article Snippet: The membrane was blocked by Intercept T20 Antibody Diluent (LI-COR Bioscience) for 1 h at room temperature on the shaker and incubated with
Techniques: Functional Assay, Concentration Assay, Expressing, Transfection
Journal: Cellular and Molecular Life Sciences
Article Title: An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
doi: 10.1007/s00018-023-04901-w
Figure Lengend Snippet: Functional characterization of disease-related TRPC6 mutants in calcium influx measurements. Changes in intracellular calcium concentration ( F / F 0 ) were measured in Fluo-4-AM-loaded HeLa cells expressing wild type (WT), P112Q, G757D, or V691Kfs* treated with doxycycline (Dox) (0.5 µg/mL) 24 h before measurement and no Dox treated cells. a – d Treatment with agonist carbachol (Cch: 100 µM): Cch was added about 20 s after the start of the measurement. Effects of TRPC6 blockers SAR7334 (SAR; 100 µM) and SH045 (100 µM) are observed in each TRPC6 mutant. e – h DOG (100 µM) was added about 20 s after the start of the measurement. Effects of SAR7334 (SAR; 100 nM) and SH045 (100 nM) are observed in each TRPC6 mutant
Article Snippet: The membrane was blocked by Intercept T20 Antibody Diluent (LI-COR Bioscience) for 1 h at room temperature on the shaker and incubated with
Techniques: Functional Assay, Concentration Assay, Expressing, Mutagenesis
Journal: Cellular and Molecular Life Sciences
Article Title: An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
doi: 10.1007/s00018-023-04901-w
Figure Lengend Snippet: Electrophysiologic characterization revealed currents mediated by WT TRPC6, TRPC6 V691Kfs*, TRPC6 P112Q, and TRPC6 WT + V691Kfs*. Whole-cell currents were recorded in transfected HEK293 cells using the protocol described in the “Materials and methods” section. After obtaining the whole-cell configuration, currents from −100 to + 100 mV were recorded during voltage ramps. a , c , e , h Inward currents at −60 mV were plotted over time. b , d , f , i Current–voltage relationships obtained during voltage ramps from −100 to + 100 mV: 1, basal currents (black); 2, 100 µM carbachol (Cch)-induced currents (red); and 3, 100 µM Cch-induced currents in the presence of 100 µM gadolinium chloride (Gd 3+ , blue). a , b Currents were measured in WT TRPC6 cells. c , d Currents were recorded in TRPC6 V691Kfs*-transfected cells. e , f Currents were recorded in TRPC6 P112Q-expressing cells. h , i Currents were recorded in TRPC6 WT + V691Kfs*-transfected cells. g Statistical analysis of the Cch-activated currents (plotted as the current density at −60 mV). Data are means ± SEMs in each group: six cells (WT TRPC6, black), seven cells (truncated TRPC6), eight cells (TRPC6 WT + V691Kfs*), and five cells (TRPC6 P112Q, gray). * P ≤ 0.05; ** P ≤ 0.01; **** P ≤ 0.0001
Article Snippet: The membrane was blocked by Intercept T20 Antibody Diluent (LI-COR Bioscience) for 1 h at room temperature on the shaker and incubated with
Techniques: Transfection, Expressing
Journal: Cellular and Molecular Life Sciences
Article Title: An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
doi: 10.1007/s00018-023-04901-w
Figure Lengend Snippet: Co-transfection strategy to characterize the dominant phenotype of TRPC6 mutants. Cells were transfected with mixtures of TRPC6 Wild Type (WT) C-terminally fused to YFP and mCherry, G757D C-terminally fused to YFP and P112Q fused to mCherry (mCh +). a – c Representative flow cytometry plots show the gating strategy to sort double-positive cells expressing both YFP and mCherry (YFP + mCh + , top right) for each co-transfected cells and the remaining 3 gates to sort cells expressing only mChr + (Top left), YFP (bottom right), and non-transfected cells (bottom left). Microscopic images of ( a ′) sorted cells expressing both WT-YFP/P112Q-mCh represented in combined image as YFP + mCh + , ( b ′) sorted cells expressing both G757D-YFP/WT-mCh represented in combined image as YFP + mCh + , ( c ′) sorted cells expressing both G757D-YFP/P112Q-mCh represented in combined image as YFP + mCh + . Scale bar 100 µm
Article Snippet: The membrane was blocked by Intercept T20 Antibody Diluent (LI-COR Bioscience) for 1 h at room temperature on the shaker and incubated with
Techniques: Cotransfection, Transfection, Flow Cytometry, Expressing
Journal: Cellular and Molecular Life Sciences
Article Title: An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis
doi: 10.1007/s00018-023-04901-w
Figure Lengend Snippet: Co-transfection strategy to characterize the dominant phenotype of TRPC6 mutants. Changes in intracellular calcium concentration ( F / F 0 ) were measured in Fluo-4-AM-loaded HeLa cells expressing wild-type (WT), P112Q/WT, G757D/WT, or P112Q/ G757D TRPC6 C-terminally fused to YFP and mCherry treated with doxycycline (Dox) (0.5 µg/mL) 24 h before measurement. a – c Carbachol (Cch: 100 µM) was added about 20 s after the start of the measurement. Effects of SAR7334 (SAR; 100 µM) and SH045 (100 µM) are observed in each TRPC6 mutant. d – f DOG (100 µM) was added about 20 s after the start of the measurement. Effects of SAR7334 (SAR; 100 µM) and SH045 (100 µM) are observed in each TRPC6 mutant. g Statistical analysis of data obtained from at least three independent experiments is presented as bar graphs. The graphs show the differences in amplitudes of the responses on Cch application h Statistical analysis of data obtained from at least three independent experiments is presented as bar graphs. The graphs show the differences in amplitudes of the responses to the DOG application ( n = 3, mean ± SEM). *** P ≤ 0.0001
Article Snippet: The membrane was blocked by Intercept T20 Antibody Diluent (LI-COR Bioscience) for 1 h at room temperature on the shaker and incubated with
Techniques: Cotransfection, Concentration Assay, Expressing, Mutagenesis